Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
DUBLIN, Nov. 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the…
102,725€
0,96%
Echtzeit-Aktienkurs Jazz Pharmaceuticals PLC
Bid:
Ask:
Nachrichten zur Jazz Pharmaceuticals PLC Aktie
Zacks.com featured highlights include Albemarle, Chevron, Jazz Pharmaceuticals and Cummins
Albemarle, Chevron, Jazz Pharmaceuticals and Cummins are part of Zacks Screen of the Week article....…
Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022
DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third…
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article....…
Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals
Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of…
Jazz Pharmaceuticals, Zymeworks in Zanidatamab License Pact
Jazz Pharmaceuticals, Zymeworks in Zanidatamab License Pact...…
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive…
Insiderhandel: Chairman & CEO verkauft Aktien von Jazz Pharmaceuticals im Wert von 6.096.906$
Cozadd, Bruce C. - Vorstand - Tag der Transaktion: 2022-10-03...…